Merck & Co., Inc.MRK
Merck & Co., Inc. Financial Overview 2021–2025
Updated Jul 10, 2026Merck’s flagship oncology drug Keytruda generated a staggering $31.7 billion in FY2025, single-handedly accounting for nearly 50% of total sales. This immense cash generation underscores a high-stakes investment thesis: Merck is a cash-rich oncology powerhouse urgently deploying capital into massive pipeline acquisitions to offset severe revenue concentration before its primary asset faces government price negotiations in 2029.
The top line has expanded reliably over the last half-decade, as total revenue grew from $48.7 billion in FY2021 to $65.0 billion in FY2025. Over that window, Keytruda sales nearly doubled from $17.2 billion, providing an unparalleled growth engine. However, the wider portfolio faces acute friction. Gardasil vaccine sales collapsed 39% in FY2025 due to deteriorating demand and inventory issues in China. To diversify away from these headwinds, management has executed aggressive buyout sprees, including the $10.5 billion purchase of Verona Pharma. These heavy research and development expenses have repeatedly distorted profitability, dragging reported earnings down to just $0.14 per share in FY2023 due to massive acquisition charges.
At the close of FY2025, the stock traded at $105.26. Merck’s financial trajectory now hinges on executing a newly announced $3.0 billion restructuring program aimed at generating $1.7 billion in annual savings by 2027, streamlining operations to bridge the gap between its current blockbusters and a newly acquired respiratory and immunology pipeline.
Recent Developments (Q4 2025 and Q1 2026)
In Q1 2026, Merck reported a $4.24 billion net loss as research and development expenses surged to $12.6 billion. This profitability drop stems from aggressive dealmaking, including the $9.2 billion acquisition of Cidara Therapeutics and an anticipated $5.8 billion charge for the pending $6.7 billion buyout of Terns Pharmaceuticals. Cash reserves plunged from $14.6 billion to $5.4 billion, prompting a $7.0 billion debt offering in May 2026.
Underlying top-line performance remains resilient with Q1 2026 sales growing 5% year-over-year to $16.3 billion. Bulls will highlight this sustained revenue growth across the oncology and animal health segments as proof the core business remains robust. Bears will argue that recurring acquisition charges are depleting cash reserves just as Januvia and Janumet face critical 2026 patent expirations. At 16.8x earnings as of May 4, 2026, the stock reflects a moderate valuation against near-term margin pressures.
What to watch: Terns Pharmaceuticals acquisition closure; Januvia and Janumet sales erosion.
Rev
$64.17B
FY2024
NI
$17.12B
FY2024
EPS
$6.76
FY2024
OCF
$21.47B
FY2024
Year-over-year comparison from 10-K annual reports
Data from SEC Company Facts
Recent SEC Filings
Merck & Co., Inc. 8-K Report, Shareholder Vote Results (May 28, 2026)
This 8-K filing from Merck & Co., Inc. (MRK) reports on the outcomes of its Annual Meeting of Shareholders held on May 26, 2026. The primary focus of the filing is the voting results on several key corporate matters. Importantly, all director nominees were elected by a substantial majority of votes cast, indicating continued shareholder confidence in the current board's leadership. Shareholders also approved the compensation of named executive officers on a non-binding advisory basis and ratified the appointment of the company's independent registered public accounting firm for 2026, with strong support for both proposals. However, the filing also highlights shareholder sentiment on ESG-related matters. Two shareholder proposals, one concerning a report on DEI risks in federal contracting and another on healthcare coverage gaps, received a very small percentage of 'FOR' votes relative to 'AGAINST' votes, suggesting limited shareholder backing for these specific initiatives at this time. Similarly, a proposal regarding political contributions also saw a significant majority vote against it. Investors should note the strong approval for governance and executive compensation matters, alongside the clear shareholder rejection of the presented ESG-focused proposals.
Merck & Co., Inc. 8-K Report, Corporate Update (May 22, 2026)
Merck & Co., Inc. (MRK) has filed an 8-K report detailing the successful closing of a significant underwritten public offering of various debt securities on May 22, 2026. The offering collectively raised substantial capital through the issuance of Floating Rate Notes due 2028 and fixed-rate notes maturing in 2028, 2031, 2033, 2036, 2046, and 2056, with aggregate principal amounts totaling $7.0 billion. This debt issuance, conducted under Merck's existing shelf registration statement, indicates the company's proactive capital management and its ability to access public debt markets to fund its operations, potential investments, or refinance existing obligations. The diverse maturity profile of the notes suggests a strategy to manage its debt obligations over the long term and potentially take advantage of prevailing interest rate conditions. Investors should monitor how these funds are deployed and their impact on Merck's financial leverage and future growth initiatives.
Merck & Co., Inc. 8-K Report, Financial Results (Apr 30, 2026)
Merck & Co., Inc. (MRK) has filed a Form 8-K on April 30, 2026, to report its financial results and condition for the first quarter of 2026. The report incorporates by reference a press release (Exhibit 99.1) and supplemental information (Exhibit 99.2) detailing the company's performance. Investors should refer to these attached documents for specific financial figures, operational updates, and forward-looking statements that provide a comprehensive view of the company's standing. While the 8-K itself doesn't contain the detailed financial data, it serves as the official notification and mechanism for investors to access Merck's first-quarter 2026 earnings. The incorporated exhibits are crucial for understanding revenue generation, profitability, key product performance, and any significant developments impacting the company's financial health and outlook. Investors are advised to review Exhibits 99.1 and 99.2 thoroughly.
Merck & Co., Inc. 8-K Report, Financial Results (Feb 3, 2026)
Merck & Co., Inc. (MRK) has filed an 8-K report on February 3, 2026, to announce its financial results for the fourth quarter and full year ended 2025. The filing incorporates by reference a press release (Exhibit 99.1) and supplemental information (Exhibit 99.2) detailing these results. While the specific financial figures are not directly presented in the 8-K text, investors are directed to the attached exhibits for a comprehensive overview of the company's performance, including key operational and financial metrics. This report serves as the primary disclosure mechanism for Merck's 2025 year-end and Q4 earnings. Investors should review Exhibits 99.1 and 99.2 for detailed insights into revenue, profitability, segment performance, and any forward-looking guidance or commentary provided by management. The information furnished is critical for understanding the company's financial health and its trajectory heading into the new fiscal year.
Merck & Co., Inc. 8-K Report, Corporate Update (Dec 4, 2025)
Merck & Co., Inc. (MRK) announced the successful closing of a significant underwritten public offering of debt securities on December 4, 2025. The offering comprised a total of eight distinct tranches of notes, raising a substantial amount of capital for the company. This move indicates Merck's strategy to secure long-term financing and potentially fund its ongoing research and development, capital expenditures, or general corporate purposes. The issuance involved notes with varying maturity dates, ranging from 2029 to 2065, and a mix of floating rate and fixed-rate instruments, suggesting a diversified approach to debt management. Investors should note that this offering represents a material increase in Merck's outstanding debt. While the specific use of proceeds is not detailed in this 8-K filing, such debt issuances are typically aimed at strengthening the company's financial flexibility and supporting its strategic initiatives. The diverse maturity profile suggests an effort to manage interest rate risk and balance short-term and long-term financing needs. Further analysis of Merck's financial statements and future disclosures will be necessary to fully understand the impact of this debt issuance on the company's capital structure and profitability.
View all 8-K filings →